The role of PET scanning in determining pharmacoselective doses in oncology drug development.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72891
Title:
The role of PET scanning in determining pharmacoselective doses in oncology drug development.
Authors:
Price, Patricia M
Abstract:
Molecular imaging is the most sensitive and specific method for measuring in vivo molecular pathways in man. Its use in oncology has developed significantly over the last 5-10 years. Molecules can be labelled with positron emitting isotopes and the emitted radiation is detected using sensitive positron emission tomography (PET) cameras. It is now possible to measure in vivo and normal tissue pharmacokinetics of anti-cancer drugs and investigate their mechanism of action. Radiolabelling of tracers can be used to measure specific pharmacodynamic endpoints and target identification. Increasing evidence shows how these technologies, when added to early drug development, can rapidly reduce the time for entry into man and early identification of mechanisms of action. With the move towards more segmented markets and identification of specific subgroups, PET's use for noninvasive biomarkers will become in- creasingly important. However, much international effort between academia and industry is required with prioritisation of development of this technology.
Affiliation:
Academic Department of Radiation Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. pat.price@manchester.ac.uk
Citation:
The role of PET scanning in determining pharmacoselective doses in oncology drug development. 2007 (59):185-93 Ernst Schering Res. Found. Workshop
Journal:
Ernst Schering Research Foundation Workshop
Issue Date:
2007
URI:
http://hdl.handle.net/10541/72891
PubMed ID:
17117724
Type:
Article
Language:
en
ISSN:
0947-6075
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPrice, Patricia M-
dc.date.accessioned2009-07-07T16:46:09Z-
dc.date.available2009-07-07T16:46:09Z-
dc.date.issued2007-
dc.identifier.citationThe role of PET scanning in determining pharmacoselective doses in oncology drug development. 2007 (59):185-93 Ernst Schering Res. Found. Workshopen
dc.identifier.issn0947-6075-
dc.identifier.pmid17117724-
dc.identifier.urihttp://hdl.handle.net/10541/72891-
dc.description.abstractMolecular imaging is the most sensitive and specific method for measuring in vivo molecular pathways in man. Its use in oncology has developed significantly over the last 5-10 years. Molecules can be labelled with positron emitting isotopes and the emitted radiation is detected using sensitive positron emission tomography (PET) cameras. It is now possible to measure in vivo and normal tissue pharmacokinetics of anti-cancer drugs and investigate their mechanism of action. Radiolabelling of tracers can be used to measure specific pharmacodynamic endpoints and target identification. Increasing evidence shows how these technologies, when added to early drug development, can rapidly reduce the time for entry into man and early identification of mechanisms of action. With the move towards more segmented markets and identification of specific subgroups, PET's use for noninvasive biomarkers will become in- creasingly important. However, much international effort between academia and industry is required with prioritisation of development of this technology.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBrain Neoplasms-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshDrug Design-
dc.subject.meshFluorodeoxyglucose F18-
dc.subject.meshHumans-
dc.subject.meshModels, Chemical-
dc.subject.meshNeoplasms-
dc.subject.meshPerfusion-
dc.subject.meshPositron-Emission Tomography-
dc.subject.meshTechnology, Pharmaceutical-
dc.subject.meshTime Factors-
dc.titleThe role of PET scanning in determining pharmacoselective doses in oncology drug development.en
dc.typeArticleen
dc.contributor.departmentAcademic Department of Radiation Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. pat.price@manchester.ac.uken
dc.identifier.journalErnst Schering Research Foundation Workshopen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.